Except IMO that’s wrong because from a purely clinical point of view Cynata cells have treated over 150 patients in various trials and is the furthest advanced from any ipsc based technology in terms of trials. Some of us who have invested are gambling that Cymerus offers the benefits of MSCs and will also be the most potent and consistent of the MSC offerings. So even if another company gets approved first doesn’t mean game over, eventually the Cynata cells get approved for something based on the merits of its own trials. Getting taken over to be shelved would mean game over and the world may never see the benefits of Cymerus which would be a tragedy.
CYP Price at posting:
20.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)